Eikon Therapeutics (EIKN) investor relations material

Executive summary

• Advanced innovative oncology medicines, with a pipeline led by EIK1001 (TLR7/8 agonist) in Phase 2/3 trials for melanoma and NSCLC, and additional candidates targeting PARP1, WRN, and AR pathways, with multiple clinical trials ongoing and new data to be presented at ASCO.

• Net loss for Q1 2026 was $83.0 million, up from $68.2 million in Q1 2025, reflecting increased R&D and G&A expenses.

• Completed IPO in February 2026, raising $348.1 million in net proceeds.

• Cash, cash equivalents, and marketable securities totaled $596.0 million as of March 31, 2026.

• Published new research on single molecule tracking technology and expanded clinical evidence supporting lead programs.

Financial highlights

• Q1 2026 revenue: $0; no product sales to date.

• Research and development expenses rose 24% year-over-year to $70.0 million, driven by clinical trial advancement and a $5.0 million milestone payment.

• General and administrative expenses increased 17% year-over-year to $17.3 million, mainly due to higher depreciation, professional fees, insurance, and recruitment costs.

• Net loss per share improved to $(2.46) from $(26.91) due to increased share count post-IPO.

• Operating cash outflow was $89.8 million for Q1 2026, up 65% year-over-year.

Outlook and guidance

• Current cash resources expected to fund operations into the second half of 2027.

• Anticipates continued increases in R&D and G&A expenses as pipeline advances and infrastructure expands.

• Plans to raise additional capital opportunistically through equity, debt, or partnerships.

• Additional clinical milestones and data readouts expected throughout 2026, including ASCO presentations.